Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cytisinicline→

Cytisinicline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
485-35-8
Molecular formula
C11H14N2O
Molecular weight
190.24 g/mol
Drug class
Nicotinic acetylcholine-receptor partial agonistsmoking-cessation agent
Mechanism of action
A plant-derived alkaloid with activity at nicotinic acetylcholine receptors, principally α4β2. It competes with nicotine for receptor binding but stimulates the receptor less strongly, helping reduce nicotine withdrawal and craving.
Indications / reported uses
  • Smoking cessation and reduction of nicotine cravings in adults who intend to stop using nicotine-containing products; the cited UK SmPC specifies a 25-day course and product-specific restrictions

Sources: UK SmPC — Cytisinicline 1.5 mg tablets · NHSBSA smoking cessation service update

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Nicotinic acetylcholine-receptor partial agonist; smoking-cessation agent

Mechanism of action

A plant-derived alkaloid with activity at nicotinic acetylcholine receptors, principally α4β2. It competes with nicotine for receptor binding but stimulates the receptor less strongly, helping reduce nicotine withdrawal and craving.

General use cases

  • Smoking cessation and reduction of nicotine cravings in adults who intend to stop using nicotine-containing products; the cited UK SmPC specifies a 25-day course and product-specific restrictions

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Cytisinicline Environmental Risk Assessment (ERA) (the Cytisinicline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.